The combination of a DNA hypomethylating agent with a histone deacetylase inhibitor has synergistic antileukemia activity and may restore sensitivity to all-trans retinoic acid (ATRA). We conducted a phase I/II study of the combination of 5-azacitidine (5-AZA), valproic acid (VPA) and ATRA in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m 2 daily x 7. VPA was dose-escalated and given orally daily x 7 concomitantly with 5-AZA. ATRA was given at 45 mg/m 2 orally daily x 5, starting on day 3. Fifty three patients were treated. Their median age was 69 years (range 5-84). The maximum tolerated dose of VPA in this combination was 50 mg/kg daily x 7. Dose limiting toxicity was reversible neurotoxicity. The overall response rate was 42%. In previously untreated older patients the response rate was 52%. Median number of courses to response was 1 (range 1-3). Median remission duration was 26 weeks and median survival has not been reached. A significant decrease in global DNA methylation and induction of histone acetylation were achieved. VPA blood levels were higher in responders (p<0.005). In conclusion the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as #NCT00326170.
INTRODUCTION
5-azacytidine (5-AZA) is a cytidine analogue with clinical activity in myelodysplastic syndromes (MDS) 1 and in acute myeloid leukemia (AML) 2, 3 . 5-AZA is a DNA methyltransferase inhibitor that induces DNA hypomethylation 4 both in vitro 5 and in vivo.
DNA methylation is a mechanism of epigenetic regulation of gene transcription 6 . It involves the addition of a methyl group to a cytosine when is followed by guanine in the so called cytosine-guanine pairs (CpG). CpGs are underrepresented in the human genome, except in areas known as CpG islands that are located near gene promoters and repetitive elements such as long interspersed nucleotide elements (LINE) 7 . DNA methylation is a physiologic process involved in imprinting and other mechanisms of gene dosage control 6 . Aberrant DNA methylation of promoter associated CpG islands is frequently detected in cancer 7 . Because methylation of promoter associated CpG islands is frequently associated with gene silencing 6 , it is considered a functional inactivating mechanism of tumor suppressor genes 7 . In contrast to deletions or mutations of tumor suppressor genes, aberrant DNA methylation is reversible both in vitro and in vivo with the use of hypomethylating agents such as 5-AZA or 5-aza-2'deoxycytidine (decitabine) 4 . The understanding of the role of 5-AZA as a modulator of DNA methylation has led to rational combination therapies exploiting mechanisms of epigenetic regulation of gene expression. One such mechanism is the biochemical modification of chromatin associated histone proteins, such as histone H3 or H4 acetylation 4 . This process is controlled by histone acetyl transferases and deacetylases (HDAC) 4, 8 . Inhibition of HDAC activity results in histone acetylation that is associated with a permissive gene expression state 8 .
A number of HDAC inhibitors have shown
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From activity in leukemia and lymphoma 8 . The combination of a hypomethylating agent with a HDAC inhibitor has synergistic effects on gene reactivation and leukemia cell kill 9, 10 . VPA, a short chain fatty acid used clinically for the treatment of epilepsy and mood disorders, is a HDAC inhibitor [11] [12] [13] . As a single agent, VPA has modest clinical activity in MDS 14 and AML 15 . In combination with decitabine, VPA has synergistic antileukemic activity in vitro 9 and in a recent clinical study, it was shown to be active in patients with poor risk leukemia 16 .
All-trans retinoic acid (ATRA) is a cell differentiation agent with clinical activity in acute promyelocytic leukemia (APL) 17 but not in other types of leukemias 18 . In APL, ATRA releases co-repressors and histone deacetylases and induces the expression of target genes 19 . In ATRA-resistant APL variants, the use of a HDAC inhibitor can restore sensitivity to ATRA 19 . In APL, DNA methyltransferases are also recruited to target gene promoters 20 . ATRA can induce hypomethylation and re-expression of the RAR-β2 gene 20 . This activity is enhanced by 5-AZA 20 . Therefore, it is possible that the combination of a hypomethylating agent with a HDAC inhibitor may sensitize ATRA resistant AML to the effects of ATRA.
Based on this information, we designed a study to test wether the combination of 5-AZA, VPA and ATRA is safe and active in patients with high risk MDS and AML.
METHODS

Study group eligibility
Patients with refractory or relapsed AML or high risk MDS, defined as having 10% or more bone marrow blasts, were included. Untreated patients over 60 years with AML or high risk MDS, who refused or were not candidates for frontline chemotherapy, were /L. A bone marrow (BM) response was defined as bone marrow blast ≤ 5% but without meeting the peripheral blood count criteria for CR or CRp. For a response to be considered, it had to last for at least 4 weeks. Remission duration was calculated from the date of first response until relapse, and survival from start of therapy until death from any cause. Bone marrow aspiration procedures were performed uniformly during course #1 of therapy pretreatment and on days 21 and 28 (+/-3 days).
On subsequent courses, they were performed on day 28 of each cycle until documentation of response and thereafter as clinically indicated.
In the phase I of the study, cohorts of 3 patients were entered at each dose level. If no Grade 3 or higher non hematological toxicity was observed, VPA was escalated to the next dose level. If one patient developed such toxicity, three more patients were accrued at that dose level. If two or more patients developed Grade 3 or higher nonhematological toxicity, that dose of VPA was considered too toxic. The MTD was defined as the dose below the one producing dose limiting toxicity (DLT) in 2 or more patients. Ten patients were to be treated at the MTD to confirm the rate of toxicity.
Toxicity was graded using the National Cancer Institute Common Toxicity Criteria (NCI CTC version 3).
The phase II was designed to evaluate the activity of the combination. The study would stop early if the probability was less than 10 % that the response rate (CR + CRp) was at least 30%. The probability of a patient response was assessed in cohorts of 10 Groups were compared using the two sample t-test. Survival and relapse-free survival were reported using Kaplan Meier curves. All p-values were two-sided; statistical significance was declared if p was below 0.05. Statistica 6.1 software was used to perform these calculations.
Cytogenetic analysis
Cytogenetic analysis was performed in the clinical cytogenetics laboratory at MDACC.
Baseline cytogenetic analysis was performed prior to therapy, and subsequently with each course of therapy when possible in patients with abnormal cytogenetics as previously described 16 .
Detection of VPA levels
Free and bound VPA levels were measured using commercially available assays on days 0, 5 and 7 of each course of therapy as previously described 16 .
Isolation of human mononuclear cells
Peripheral blood human mononuclear cells were used to perform DNA methylation and mRNA studies. Peripheral blood specimens from patients were drawn into heparin (30 U/ml) containing tubes. Mononuclear cells were separated using Ficoll-Paque TM PLUS gradient centrifugation (Amersham Biosciences AB, Uppsala, Sweden). The monocyteenriched fraction was collected and washed twice with calcium and magnesium free
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Analysis of DNA Methylation
To study the dynamics of DNA hypomethylation during treatment, we sequentially studied LINE methylation, a marker of global DNA methylation 16 . To do so we used a bisulfite pyrosequencing assay 16 . The details of this technique have been described elsewhere 16 .
Analysis of Histone acetylation
Histone H3 and H4 acetylation was analyzed by Western blot using antibodies directed against acetylated histone H3 and H4 as previously described 16 . In brief, proteins were isolated from peripheral blood mononuclear cells by sonication, using a lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0. 
Real-time PCR analysis of p21
CIP1 and p15 mRNA gene expression P21 CIP1 and p15 mRNA expression was conducted as previously described 16 . In summary, total cellular RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). Two to three µg of total RNA were used for reverse transcription (RT) reactions using the 
RESULTS
Study group
Fifty-three patients were treated. Patient characteristics are shown in Table 1 . Nineteen patients were treated during the phase I portion of the study, and 34 during the phase II, which included 10 patients that were an expansion cohort treated at the MTD. Thirtythree patients (62%) were older than 60 years and had previously untreated disease.
These patients refused or were not considered candidates for frontline intensive chemotherapy. Thirty-four patients (64%) had poor-risk cytogenetics.
Valproic acid dose escalation and toxicities
Three dose levels of VPA (50, 62.5 and 75 mg/kg orally daily for 7 days) were explored in combination with 5-AZA and ATRA. No grade 3-4 non-hematologic toxicity attributable to 5-AZA or ATRA was observed at any dose level. The number of patients who experienced Grade 3-4 toxicities related to therapy during the first course of therapy is shown in Table 2 . We assessed toxicities in cohorts of three patients. The starting dose of VPA was 50 mg/kg. One of the first 3 patients experienced a DLT (Grade 3 neurotoxicity), and 3 more patients were enrolled in that cohort. Subsequently, the dose was escalated to 62.5 mg/kg orally daily for 7 days. The first 3 patients enrolled in this cohort did not experienced DLTs and the dose of VPA was further increased to 75 mg/kg orally daily for 7 days. One of the first 3 patients at this dose level experienced a DLT. Three more patients were enrolled at this dose level with one additional patient developing toxicity. Subsequently, VPA was decreased to 62.5 mg/kg orally daily for 7 days. DLTs were observed in 2 additional patients at this dose level, and VPA was decreased again to 50 mg/kg which was declared as the MTD after treating 10 patients at this dose level. Subsequently, a total of 34 patients were treated in the phase II at the MTD, including 10 patients in the expanded phase I cohort at the MTD. Table 3 summarizes the most frequent toxicities during course 1 and thereafter.
Most frequent events included neurotoxicities, mainly somnolence and confusion, followed by fatigue. Toxicities were transient and reversible. Only 3 out of 53 patients (5%) died during induction, none of them was previously untreated. Overall, there were no differences in terms of toxicities between the previously untreated group and those patients that had received prior therapy, nor between responding patients and those that did not achieve a response.
Because the entry criteria for the study allowed patients to be off prior chemotherapy for just 2 weeks, we analyzed the impact of prior therapy on this group of patients. Of the 20 previously treated patients, only 3 were treated less than 1 month after their prior 3 rd , 4 th and 5 th salvage attempts. All were taken off because of no response. No toxicity was observed. The median time after last therapy was 2 months (range 0.5 to 72).
Therefore, prior therapy did not seem to have an impact on response or toxicity.
Clinical activity
Responses are summarized in Table 4 . An overall response rate of 42% was observed. 
Overall, the median number of courses of therapy administered was 2 (1-10+). In the untreated patients over 60 years it was 3 (1-10+). The median number of courses to first response was 1 (range 1-3). Among 4 patients with high risk MDS, 2 achieved CR and 2 a bone marrow response.
Cytogenetic responses
Pretreatment cytogenetic characteristics are shown in Table 5 . Five out of 8 patients (62%) with poor risk cytogenetics had a response. Four of 11 responders with informative cytogenetics achieved a cytogenetic response (36%). Two had a complete cytogenetic response, and 2 a partial cytogenetic response.
Valproic acid levels
VPA levels were measured sequentially pretreatment on day 0, and prior to drug administration on days 5 and 7. Free (mg/L) and bound (µg /mL) VPA levels during cycle 1 are shown in Table 6 . The median free and bound VPA levels on days 5 and 7
were significantly higher in patients achieving a response. Median free VPA level on day 5 in responders was 36.8 mg/L (range 29.4-61.6 mg/L) whereas it was 21.6 (range 4.2-46.4) in non responders (p<0.005). Median bound VPA level on day 5 was 132 mcg/ml (69-202 mcg/ml) in responders and 104 mcg/ml (26-165 mcg/ml) in nonresponders (p<0.005). A similar pattern was observed on day 7 (Table 6 ). Despite the association between VPA blood levels and response, there was no association between dose level and response.
Induction of Histone Acetylation
Histone H3 and H4 acetylation was evaluated using western blots on days 0, 2, 7 and 21 in 48 patients. Histone acetylation was detected in 26 patients (54%). The frequency of histone acetylation per dose level is shown in Figure 3 . There was no correlation between VPA dose level and histone acetylation or histone acetylation and response.
DNA methylation Analysis
To study the DNA methylation dynamics during treatment, global DNA methylation was analyzed on days 0, 2, 7 and 21. We used the LINE pyrosequencing assay which is a surrogate marker of global methylation 21 . We found a significant decrease in global methylation by day 7, the last day of treatment, with a return towards baseline by day 0 of the next cycle as shown in figure 4 . The degree of global DNA hypomethylation achieved during treatment was not different between responders and non responders.
Induction of p21 and p15 mRNA expression
We measured the expression of p21 and p15 mRNA pretreatment and sequentially on days 7 and 21 in 43 patients with available samples. Results are shown on figure 5.
Although a modest but significant increment on p15 and p21 mRNA expression was detected, this was not associated with clinical response.
Subset analysis of pediatric patients
Three patients ages 5, 15 and 18 were treated in this study. All of them had relapsed or refractory AML. A 15 years old patient achieved a bone marrow response during therapy but died after 9 weeks. No significant toxicities were observed in this age group. Two of the patients had evidence of histone acetylation. No difference in the dynamics of DNA hypomethylation was observed between children and adults (data not shown).
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DISCUSSION
In this study, we demonstrated that the combination of 5-AZA, VPA at 50 mg/kg orally daily for 7 days, and ATRA was safe. This combination was also active and associated with induction of global DNA hypomethylation and histone acetylation. We defined the MTD of VPA to be 50 mg/kg orally for 7 days. This is consistent with our prior experience with decitabine and VPA, where a dose of 50 mg/kg orally for 10 days could be tolerated 16 . VPA administration at these doses was associated with reversible neurotoxicity which resolved shortly after drug interruption. No significant toxicities related to 5-AZA or ATRA administration were observed. In particular, no evidence of acute cell differentiation syndrome (i.e. ATRA syndrome) was observed in any patient.
The overall treatment mortality was 5%: 3 patients, all of them with relapsed/refractory disease, died during induction. The combination of 5-AZA, VPA and ATRA, was clinically active: the overall response rate was 42%, including 12 CRs (22%). In the subset of patients over 60 years with previously untreated disease, the response rate was 52% with no induction deaths. Their median survival has not been reached. Patients age 2 and older were allowed to be enrolled in our study. The reason for the age restriction was the reported hepatotoxicity of VPA when used in patients less than 2 years old 22,23 24 . In our study the combination of 5-AZA, VPA and ATRA was safe in the 3 pediatric patients with relapsed/ refractory AML, and one bone marrow response was observed. These findings are similar to the results with the combination of VPA and decitabine 16 . Combinations of VPA with 5-AZA or decitabine, and ATRA need to be further explored in specific pediatric phase I studies in leukemia.
In this study, we evaluated four potential biomarkers: VPA levels, histone acetylation, induction of global DNA hypomethylation, and induction of p21 and p15 mRNA expression. First, higher VPA levels were demonstrated in patients who responded versus those that did not. This is consistent with our in vitro data that indicate that the antileukemic effect of VPA is directly related to its concentration 9 , and with our previous study of decitabine and VPA 16 , in which untreated patients with higher VPA levels had a higher response rate. The implications of these findings are important in that replacement of VPA with a more potent HDAC inhibitor with a better toxicity profile may improve the activity and tolerability of this type of combination. Another potential implication is the specific targeting of plasma levels of VPA in future clinical trials, instead of using doses based on weight. Second, HDAC inhibition resulted in histone acetylation. Consistent with the in vitro HDAC inhibitory effect, we observed that 54% of While the regimen was safe and active, we did not prove that the combination is superior to single agent 5-AZA as this study was not designed to test that hypothesis.
This should be tested in a randomized study. Our results suggest that the combination may be superior. An analysis by Silverman et al Acknowledging this limitation, the response rate in patients over 60
years was 52%, the complete response rate was 33%, and the median number of courses to response was 1 (1-3) which may support the contribution of VPA and ATRA to the single agent activity of 5-AZA. Furthermore, VPA levels were higher in patients achieving a response VPA has been used as a single agent or in combination with ATRA in patients with MDS 14,28 and AML 15, 28, 29 . Kuendgen et al 15 reported 58 patients with AML treated with single agent VPA or in combination with ATRA who were not considered candidates for intensive chemotherapy. The response rate was 5 %. In that study, VPA levels of 50 to 100 µ g/ml were targeted. HDAC inhibition is observed at concentrations of VPA greater than 1mM 9 . This is greater than the concentration achieved with targeted VPA levels of 50 to 100 µ g/ml used in the treatment of seizures. These low levels of VPA may explain the low number of responses observed in that study 15 . The higher levels of VPA For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From achieved in our study, particularly in responders, support a role of VPA in this combination.
There are several limitations in our study. First, 5-AZA was used at 75 mg/m 2 subcutaneously daily for 7 days, although this is the same 5-AZA dose used in the CALGB studies in patients with high risk MDS 1, 3 ; it is unknown if this is the most effective dose and it is possible that other schedules and doses may be better. Second, VPA, the HDAC inhibitor used in this study, is one of the less effective HDAC inhibitors and its use a high concentration is associated with potential serious toxicities. The combination of 5-AZA with more effective and less toxic HDAC inhibitors may improve the results observed in this trial. A study combining 5-AZA with MGCD0103, an oral isotype selective HDAC inhibitor is currently ongoing with promising interim results 30 .
Third, so far we have not found a molecular marker predictive of response as both global DNA methylation and histone acetylation were not different in responders.
Further ongoing molecular analysis of gene specific methylation, gene expression and effects downstream of histone acetylation may unravel such molecular predictors.
Fourth, the role of ATRA in this combination has not been defined. We had based the decision to add it to the combination based on data from Kuendgen et al described above 14 , and by the observation that the addition of 5-aza-2'-deoxycitidine to ATRA could result in apoptosis in ATRA-refractory leukemia cell lines 31 . Also, ATRA can induce cell differentiation and has clinical activity in APL 17 but not in non-APL leukemias 18 . In ATRA-resistant APL variants, the use of a HDACI like VPA can restore sensitivity to ATRA 20, 32, 33 . Based on this, and on the experience of Kuendgen et al 14, 15 with VPA in combination with ATRA in MDS and AML, we added ATRA to the combination of 5-AZA and VPA. That said, in this study we have not determined the contribution of ATRA in this combination. Fifth, in this study we have not systematically studied the effects of therapy on cell differentiation. In vitro, the combination had no effect on cell differentiation 9 , nor have we observed any case of ATRA-syndrome or morphological evidence of differentiation. That said, detailed flow cytometry studies could clarify this issue.
Finally, one remaining issue pertains to the schedule used here. We elected to administer these agents concomitantly. This was based on our prior experience with 5-aza-2'-deoxcytidine and valproic acid 16 and in vitro models that indicated no advantage to a sequential administration 9 . That said, in vitro data looking at gene reactivation have suggested a benefit to the sequential administration of these agents 34 . Therefore it is possible that other schedules may result in enhance clinical activity.
In summary, this study demonstrated that the combination of 5-AZA, VPA and ATRA is safe and active. This therapy was associated with significant DNA hypomethylation and induction of histone acetylation. Despite of clinical activity observed in particular in the older untreated patients, the number of patients treated was small and this combination should be considered investigational and should not be recommended outside the setting of a clinical trial.
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